The PROPHY-VAP Trial: Ceftriaxone to Prevent VAP in Patients with Acute Brain Injury
RebelEM
FEBRUARY 29, 2024
The authors rightfully note future research targets should include how/if the routine use of ceftriaxone increases antibiotic resistance in a population that is already quite vulnerable to devastating infection. 8 Author’s Conclusion: “In patients with acute brain injury, a single ceftriaxone dose decreased the risk of early VAP.” .;
122 
Let's personalize your content